Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostics company, utilizes microRNAs, a collection of recently discovered non-coding control genes, to develop a broad array of tests for cancers and women’s health indications. These non-coding genes have demonstrated to be highly sensitive and tissue specific biomarkers. The company’s early recognition of microRNAs’ vast potential has led to great discovery and has the establishment of a leading intellectual property (IP) portfolio. For further information, visit the Company’s web site at www.rosettagenomics.com.
- 17 years ago
QualityStocks
Rosetta Genomics, Ltd. (NASDAQ: ROSG)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – SolarBank Corp.’s (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Forest Hill Rd Project Adds to Growing Development Pipeline
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) was featured…
-
QualityStocksNewsBreaks – Driving the Future of Powersports: Massimo Group’s (NASDAQ: MAMO) Bold Strategy for Market Growth
As the powersports and recreational watercraft industries experience a notable upswing, Massimo Group (NASDAQ: MAMO) is taking…
-
QualityStocksNewsBreaks – Why Beeline Holdings Inc. (NASDAQ: BLNE) Is ‘One to Watch’
Beeline Holdings (NASDAQ: BLNE) is a technology-forward mortgage and title platform leveraging AI, automation, and intuitive…